Advancing therapeutics and vaccines against sarbecoviruses
CoV Biotechnology is an early-stage Singapore-based biotechnology company focusing on inducing broad, pan-sarbecovirus immune responses to address the evolving and mutating nature of the coronavirus. The company is developing booster vaccines and therapeutics that are effective against variants of SARS-2 beta coronavirus, to protect against future variants and future crossovers of related coronaviruses from animal to humans.
CoV Biotechnology is an early-stage Singapore-based biotechnology company focusing on inducing broad, pan-sarbecovirus immune responses to address the evolving and mutating nature of the coronavirus. The company is developing booster vaccines and therapeutics that are effective against variants of SARS-2 beta coronavirus, to protect against future variants and future crossovers of related coronaviruses from animal to humans.
For our vaccine products, we believe that a cross-clade vaccine boosting strategy can induce broad spectrum immune responses against a wide range of sarbecoviruses. This will help us stay ahead of the virus mutations.
For our vaccine products, we believe that a cross-clade vaccine boosting strategy can induce broad spectrum immune responses against a wide range of sarbecoviruses. This will help us stay ahead of the virus mutations.
For our antibody assets, we have developed antibodies that have broad neutralizing activities against sarbecoviruses in the SARS-1, SARS-2 and zoonotic clades. These antibodies can be used as therapeutics in people who are at risk of developing severe COVID-19 disease, or for prevention of sarbecovirus infections in immunocompromised individuals.
For our antibody assets, we have developed antibodies that have broad neutralizing activities against sarbecoviruses in the SARS-1, SARS-2 and zoonotic clades. These antibodies can be used as therapeutics in people who are at risk of developing severe COVID-19 disease, or for prevention of sarbecovirus infections in immunocompromised individuals.
Our Team
Our Team
Dr Rosemary Tan is the Chief Exective Officer of CoV Biotechnology. She received her BSc from the University of Calgary, Canada before going to the Institute of Cell and Molecular Biology, Osaka University and the Department of Immunology at the Medical School in the University of Tokyo, under an EDB – Ishihara Sangyo Kaisha scholarship. She obtained her PhD from NUS and has published widely in immunology and on the genetic basis of cancer and diseases. She was a recipient of the Naito Science Award.
Dr Rosemary Tan is the Chief Exective Officer of CoV Biotechnology. She received her BSc from the University of Calgary, Canada before going to the Institute of Cell and Molecular Biology, Osaka University and the Department of Immunology at the Medical School in the University of Tokyo, under an EDB – Ishihara Sangyo Kaisha scholarship. She obtained her PhD from NUS and has published widely in immunology and on the genetic basis of cancer and diseases. She was a recipient of the Naito Science Award.
Prior to joining CoV Biotechnology, Dr Tan founded Veredus Laboratories and successfully led the company for more than 20 years. Under her leadership, Veredus supported key national efforts during the SARS-1, H1N1, H5N1 and the SARS-2 pandamic.
Prior to joining CoV Biotechnology, Dr Tan founded Veredus Laboratories and successfully led the company for more than 20 years. Under her leadership, Veredus supported key national efforts during the SARS-1, H1N1, H5N1 and the SARS-2 pandamic.
Professor Linfa Wang is the Scientific Founder and Chief Scientific Officer of CoV Biotechnology. He is currently a Professor in the Programme in Emerging Infectious Diseases at Duke-NUS Medical School and the inaugural Executive Director of the Programme for Research in Epidemic Preparedness and Response (PREPARE), Singapore. He is one of the world’s leading experts in zoonotic diseases, pathogen discovery and bat immunology, having co-authored more than 500 scientific papers including many top scientific publications in Science, Nature, New England Journal of Medicine and Lancet.
Professor Linfa Wang is the Scientific Founder and Chief Scientific Officer of CoV Biotechnology. He is currently a Professor in the Programme in Emerging Infectious Diseases at Duke-NUS Medical School and the inaugural Executive Director of the Programme for Research in Epidemic Preparedness and Response (PREPARE), Singapore. He is one of the world’s leading experts in zoonotic diseases, pathogen discovery and bat immunology, having co-authored more than 500 scientific papers including many top scientific publications in Science, Nature, New England Journal of Medicine and Lancet.
Prof Wang has served on multiple committees and advisory boards for various international agencies including World Health Organization (WHO) and Coalition for Epidemic Preparedness Innovations (CEPI) since the start of the COVID-19 pandemic, and is internationally recognised as an expert in coronaviruses. The recent discovery from his team laid the scientific foundation for CoVBio’s mission to develop broad spectrum vaccines and therapeutic monoclonal antibodies.
Prof Wang has served on multiple committees and advisory boards for various international agencies including World Health Organization (WHO) and Coalition for Epidemic Preparedness Innovations (CEPI) since the start of the COVID-19 pandemic, and is internationally recognised as an expert in coronaviruses. The recent discovery from his team laid the scientific foundation for CoVBio’s mission to develop broad spectrum vaccines and therapeutic monoclonal antibodies.
Our Partners
Our Partners
Technology Overview
Technology Overview
In our publication in the New England Journal of Medicine [N Engl J Med, 35;15, Oct 7 2021], we validated a cross-clade boosting strategy that can induce broad spectrum protection against sarbecoviruses. We showed that 2003 SARS-1 survivors who were vaccinated with the Pfizer-BioNTech (BNT162n2) vaccine in 2021 produced high levels of antibodies that were broadly neutralizing to all tested viruses including zoonotic sarbecoviruses. Furthermore, the conserved epitopes in SARS-1 and SARS-2 bypassed the original antigenic sin effect and thus inducing broadly neutralizing antibodies.
In our publication in the New England Journal of Medicine [N Engl J Med, 35;15, Oct 7 2021], we validated a cross-clade boosting strategy that can induce broad spectrum protection against sarbecoviruses. We showed that 2003 SARS-1 survivors who were vaccinated with the Pfizer-BioNTech (BNT162n2) vaccine in 2021 produced high levels of antibodies that were broadly neutralizing to all tested viruses including zoonotic sarbecoviruses. Furthermore, the conserved epitopes in SARS-1 and SARS-2 bypassed the original antigenic sin effect and thus inducing broadly neutralizing antibodies.
Pipeline and Products
Pipeline and Products
Our findings led to the development of:
Our findings led to the development of:
- Consensus vaccine sequences for broad spectrum sarbecovirus production
- Neutralizing antibody seuqences isolated from SARS-1 survivor vaccined with SARS-2 vaccine.
Our monoclonal antibody assets and vaccine assets aim to prevent and treat sarbecovirus infections. These can be formulated into a range of products against sarbecoviruses.
Our monoclonal antibody assets and vaccine assets aim to prevent and treat sarbecovirus infections. These can be formulated into a range of products against sarbecoviruses.
Antibodies
Antibodies
Protein sub-unit vaccine
Protein sub-unit vaccine
mRNA vaccine
mRNA vaccine
Nasal spray
Nasal spray
Contact Us
Contact Us